New insights into cellular responses to cisplatin

Cisplatin: Pharmacology, Clinical Uses and Adverse Effects

Volumn , Issue , 2012, Pages 1-26

  Ratanaphan, Adisorn ^a  

^a PRINCE OF SONGKLA UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892049487     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (193)

1. Aebi, S., Kurdi-Haidar, B., Gordon, R., Cenni, B., Zheng, H., Fink, D., et al. (1996). Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res. 56(13): 3087-3090.
2. Alli, E., Sharma, V. B., Hartman, A. R., Lin, P. S., McPherson, L. & Ford, J. M. (2011). Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells. BMC Pharmacol. 11: 7.
3. Amir, E., Seruga, B., Serrano, R. & Ocana A. (2010). Targeting DNA repair in breast cancer: A clinical and translational update. Cancer Treat Rev. 36(7): 557-565.
4. Andrews, P. A., Jones, J. A., Varki, N. M. & Howell, S. B. (1990). Rapid emergence of acquired cis-diamminedichloroplatinum(II) resistance in an in vivo model of human ovarian carcinoma. Cancer Comm. 2(2): 93-100.
5. Andrews, P.A., Murphy, M.P. & Howell, S.B. (1987). Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother Pharmacol. 19(2): 149-154.
6. Araujo, S.J., Tirode, F., Coin, F., Pospiech, H., Syvaoja, J.E., Stucki, M., et al. (2000). Nucleotide excision repair of DNA with recombinant human proteins: definition of the minimal set of factors, active forms of TFIIH, and modulation by CAK. Genes Dev. 14(3): 349-359.
7. Ashworth, A. (2008). A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol. 26(22): 3785-3790.
8. Atipairin, A., Canyuk, B. & Ratanaphan, A. (2010). Cisplatin affects the conformation of apo-form, not holo-form, of BRCA1 RING finger domain and confers thermal stability. Chem Biodivers. 7(8): 1949-1967.
9. Atipairin, A., Canyuk, B. & Ratanaphan, A. (2011a). The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by the platinum-based anticancer drugs. Breast Cancer Res Treat. 126(1): 203-209.
10. Atipairin, A., Canyuk, B. & Ratanaphan, A. (2011b). Substitution of aspartic acid with glutamic acid at position 67 of BRCA1 RING domain retains ubiquitin ligase activity and zinc(II)-binding with a reduced transition temperature. J Biol Inorg Chem. 16(2): 217-226.
11. Ban, N., Takahashi, Y., Takayama, T., Kura, T., Katahira, T., Sakamaki, S., et al. (1996). Transfection of glutathione S-transferase (GST)-π antisense complementary DNA increases the sensitivity of a colon cancer cellline to adriamycin, cisplatin, melphalan, and etoposide. Cancer Res. 56(15): 3577-3582.
12. Bassett, E., King, N.M., Bryant, M.F., Hector, S., Pendyala, L., Chaney, S.G., et al. (2004). The role of DNA polymerase eta in translesion synthesis past platinum-DNA adducts in human fibroblasts. Cancer Res. 64(18): 6469-6475.
13. Bassett, E., Vaisman, A., Havener, J.M., Masutani, C., Hanaoka, F. & Chaney, S.G. (2003). Efficiency of extension of mismatched primer termini across from cisplatin and oxaliplatin adducts by human DNA polymerases beta and eta in vitro. Biochemistry. 42(48): 14197-14206.
14. Basu, A. & Cline, J.S. (1995). Oncogenic transformation alters cisplatin-induced apoptosis in rat embryo fibroblasts. Int J Cancer. 63(4): 597-603.
15. Bedford, P., Fichtinger-Schepman, A.M., Shellard, S.A., Walker, M.C., Masters, J.R.W. & Hill, B.T. (1988). Differential repair of pt-DNA adducts in human bladder and testicular tumor continuous cell lines. Cancer Res. 48(11): 3019-3024.
16. Bellon, S.F., Coleman, J.H. & Lippard, S.J. (1991). DNA unwinding produced by sitespecific intrastrand cross-links of the antitumor drug cis-diamminedichloroplatinum(II). Biochemistry. 30(32): 8026-8035.
17. Berek, J.S. & Hacker, N.F. (1990). Ovary and fallopain tubes, In: Cancer treatment, (ed.) Haskell, C.M., Saunders, W.B., Philadelphia, pp. 295-325.
18. Berners-Price, S.J., Frenkiel, T.A., Frey, U., Ranford, J.D. & Sadler, P.J. (1992). Hydrolysis products of cisplatin: pKa determinations via [1H,15N] NMR spectroscopy. J Chem Soc., Chem Commun. 789-791.
19. Bernges, F. & Holler, E. (1991). The reaction of platinum(II) complexes with DNA. Kinetics of intrastrand crosslink formation in vitro. Nucleic Acids Res. 19(7): 1483-1489.
20. Bohr, V.A., Phillips, D.H. & Hanawalt, P.C. (1987). Heterogenous DNA damage and repair in the mammalian genome. Cancer Res. 47: 6426-6436.
21. Bose, R.N., Yang, W.W. & Evanics, F. (2005). Structural perturbation of a C4 zinc-finger module by cis-diamminedichloroplatinum(II): insights into the inhibition of transcription processes by the antitumor drug. Inorg Chim Acta. 358(10): 2844-2854.
22. Boulikas, T. (2009). Clinical overview on Lipoplatin: a successful liposomal formulation of cisplatin. Expert Opin Invest Drugs. 18(8): 1197-1218.
23. Byrski, T., Huzarski, T., Dent, R., Gronwald, J., Zuziak, D., Cybulski, C., et al. (2009). Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat. 115(2): 359-363.
24. Casini, A., Gabbiani, C., Michelucci, E., Pieraccini, G., Moneti, G., Dyson, P.J., et al. (2009). Exploring metallodrug-protein interactions by mass spectrometry: comparisons between platinum coordination complexes and an organometallic ruthenium compound. J Biol Inorg Chem. 14(5): 761-770.
25. Casini, A., Guerri, A., Gabbiani, C. & Messori, L. (2008). Biophysical characterisation of adducts formed between anticancer metallodrugs and selected proteins: New insights from X-ray diffraction and mass spectrometry studies. J Inorg Biochem. 102(5-6): 995-1006.
26. Casini, A., Mastrobuoni, G., Temperini, C., Gabbiani, C., Francese, S., Moneti, G., et al. (2007). ESI mass spectrometry and X-ray diffraction studies of adducts between anticancer platinum drugs and hen egg white lysozyme. Chem Commun. 14(2): 156-158.
27. Chen, D., Ohta, N., Ukai, M., Masuda, M. & Yotsuyanagi T. (1994). Binding and aggregation of human γ-globulin by cis-diamminedichloroplatinum (II) through disulfide bond. Biol Pharm Bull. 17(12): 1561-1566.
28. Cohen, G.L., Ledner, J.A., Bauer, W.R., Ushay, H.M., Caravana, C. & Lippard, S.J. (1980). Sequence dependent binding of cis-dichlorodiammineplatinum(II) to DNA. J Am Chem Soc. 102(7): 2487-2488.
29. Coley, R.F. & Martin, D.S. (1973). Kinetics and equilibria for the acid hydrolysis of dichloro(ethylenediammine)platinum(II). Inorg Chim Acta. 7: 573-577.
30. Corda, Y., Job, C., Anin, M-F., Leng, M. & Job, D. (1991). Transcription by eukaryotic and prokaryotic RNA polymerases of DNA modified at a d(GG) or a d(AG) site by the antitumor drug cis-diamminedichloroplatinum(II). Biochemistry. 30(1): 222-230.
31. Corda, Y., Job, C., Anin, M.F., Leng, M. & Job, D. (1993). Spectrum of DNA- platinum adduct recognition by prokaryotic and eukaryotic DNA dependent RNA polymerase. Biochemistry. 32(33): 8582-8588.
32. Corda, Y., Anin, M.F., Leng, M. & Job, D. (1992). RNA polymerases react differently at d(ApG) and d(GpG) adducts in DNA modified by cis-diamminedichloroplatinum(II). Biochemistry. 31(7): 1904-1908.
33. Cox, M.C., Barnham, K.J., Frenkiel, T.A., Hoeschele, J.D., Mason, A.B., He, Q-Y., et al. (1999). Identification of platination sites on human serum transferrin using 13C and 15N NMR spectroscopy. J Biol Inorg Chem. 4(5): 621-631.
34. Crider, S.E., Holbrook, R.J. & Franz, K.J. (2010). Coordination of platinum therapeutic agents to met-rich motifs of human copper transport protein 1. Metallomics. 2(1): 74-83.
35. Cubo, L., Thomas, D.S., Zhang, J., Quiroga, A.G., Navarro-Ranninger, C. & Berners-Price, S.J. (2009). [1H,15N] NMR studies of the aquation of cis-diamine platinum(II) complexes. Inorg Chim Acta. 362(3): 1022-1026.
36. Cullinane, C., Mazur, S.J., Essigmann, J.M., Phillips, D.R. & Bohr, V.A. (1999). Inhibition of RNA polymerase II transcription in human cell extracts by cisplatin DNA damage. Biochemistry. 38(19): 6204-6212.
37. Custodio, J.B.A., Cardoso, C.M.P., Santos, M.S., Almeida, L.M., Vicente, J.A.F. & Fernandes, M.A.F. (2009). Cisplatin impairs rat liver mitochondrial functions by inducing changes on membrane ion permeability: Prevention by thiol group protecting agents. Toxicology. 259(1-2): 18-24.
38. de Paula, Q.A., Mangrum, J.B. & Farrell, N.P. (2009). Zinc finger proteins as templates for metal ion exchange: Substitution effects on the C-finger of HIV nucleocapsid NCp7 using M(chelate) species (M=Pt, Pd, Au). J Inorg Biochem. 103(10): 1347-1354.
39. Dhar, R. & Basu, A. (2008). Costitutive activation of p70 S6 kinase is associated with intrinsic resistance to cisplatin. Int J Oncol. 32(5): 1133-1137.
40. Dijt, F.J., Fichtinger-Schepman, A.M., Berends, F. & Reedijk, J. (1988). Formation and repair of cisplatin-induced adducts to DNA in cultured normal and repair-deficient human fibroblasts. Cancer Res. 48(21): 6058-6062.
41. Donahue, B.A., Augot, M., Bellon, S.F., Treiber, D.K., Toney, J.H., Lippard, S.J., et al. (1990). Characterization of a DNA damage-recognition protein from mammalian cells that binds specifically to intrastrand d(GpG) and d(ApG) DNA adducts of the anticancer drug cisplatin. Biochemistry. 29(24): 5872-5880.
42. Drummond, J.T., Anthoney, A., Brown, R. & Modrich, P. (1996). Cisplatin and adriamycin resistance are associated with MutLα and mismatch repair deficiency in an ovarian tumor cell line. J Biol Chem. 271(33): 19645-19648.
43. Du, W., Li, Z., Wang, B. & Zhang, Y. (1999). A study on the interaction between cisplatin and urease. Thermochim Acta. 333(2): 109-114.
44. Eastman, A. (1983). Characterization of the adducts produced in DNA by cisdiamminedichloroplatinum(II) and cis-dichloro(ethylenediammine) platinum(II). Biochemistry. 22(16): 3927-3933.
45. Eastman, A. (1986). Reevaluation of interaction of cis-dichloro (ethylenediamine) platinum (II) with DNA. Biochemistry. 25(13): 3912-3915.
46. Eastman, A. (1987). The formation, isolation, and characterization of DNA adducts produced by anticancer platinum complexes. Pharmacol Ther. 34(2): 155-166.
47. Esteller, M. (2007). Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet. 8(4): 286-298.
48. Fan, S., Smith, M.L., Rivet, D.J., Duba, D., Zhan, Q., Kohn, K.W. et al. (1995). Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res. 55: 1649-1654.
49. Farmer, H., McCabe, N., Lord, C.J., Tutt, A.N., Johnson, D.A., Richardson, T.B., et al. (2005). Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 434(7035): 917-921.
50. Fedier, A., Steiner, R.A., Schwarz, V.A., Lenherr, L., Haller, U. & Fink, D. (2003). The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells. Int J Oncol. 22(5): 1169-1173.
51. Fichtinger-Schepman, A.M.J., Lohman, P.H.M. & Reedijk, J. (1982). Detection and quantification of adducts formed upon interaction of diamminedichloroplatinum(II) with DNA, by anion-exchange chromatography after enzymatic degradation. Nucleic Acids Res. 10(17): 5345-5356.
52. Fichtinger-Schepman, A.M.J., van der Veer, J.L., den Hartog, J.H.J., Lohman, P.H.M. & Reedijk, J. (1985). Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation. Biochemistry. 24(3): 707-713.
53. Fichtinger-Schepman, A.M.J., van Oosterom, A.T., Lohman, P.H.M. & Berends, F. (1987a). Interindividual human variation in cisplatinum sensitivity, predictable in an in vitro assay. Mutat Res. 190(1): 59-62.
54. Fichtinger-Schepman, A.M.J., van Oosterom, A.T., Lohman, P.H.M. & Berends, F. (1987b). cis-Diamminedichloroplatinum(II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: quantitative immunochemical detection of the adduct induction and removal after a single dose of cis-diamminedichloroplatinum(II). Cancer Res. 47(11): 3000-3004.
55. Fink, D., Nebel, S., Aebi, S., Nehme, A. & Howell, S.B. (1997). Loss of DNA mismatch repair due to knockout of MSH2 or PMS2 results in resistance to cisplatin and carboplatin. Intl J Oncol. 11(3): 539-542.
56. Fink, D., Nebel, S., Aebi, S., Zheng, H., Cenni, B., Nehme, A. et al. (1996). The role of DNA mismatch repair in platinum drug resistance. Cancer Res. 56(21): 4881-4886.
57. Fink, D., Nebel, S., Norris, P.S., Baergen, R.N., Wilczynski, S.P., Costa, M.J., et al. (1998). Enrichment for DNA mismatch repair-deficient cells during treatment with cisplatin. Int J Cancer. 77(5): 741-746.
58. Folbergrova, J., Lisa, V., Drobnik, J. & Mares, V. (1987). Cyclic AMP levels of C6 glioma cells treated with cis-dichlorodiammineplatinum (cis-DDP). Neoplasma. 34(1): 3-13.
59. Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., et al. (2009). Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 361(2): 123-134.
60. Font, A., Taron, M., Gago, J.L., Costa, C., Sánchez, J.J., Carrato, C., et al. (2010). BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer. Ann Oncol. doi:10.1093/annonc/mdq333.
61. Gately, D.P. & Howell, S.B. (1993). Cellular accumulation of the anticancer agent cisplatin: A review. Br J Cancer. 67(6): 1171-1176.
62. Godwin, A.K., Meister, A., O'Dwyer, P.J., Huang, C.S., Hamilton, T.C. & Anderson, M.E. (1992). High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci. USA. 89(7): 3070-3074.
63. Hall, M.D., Okabe, M., Shen, D.W., Liang, X.J. & Gottesman, M.M. (2008). The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol. 48: 495-535.
64. Hartman, A-R. & Ford, J.M. (2003). BRCA1 and p53: compensatory roles in DNA repair. J Mol Med. 81(11): 700-707.
65. Hastak, K., Alli, E. & Ford, J.M. (2010). Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin. Cancer Res. 70(20): 7970-7980.
66. Helleday, T., Petermann, E., Lundin, C., Hodgson, B. & Sharma, R.A. (2008). DNA repair pathways as targets for cancer therapy. Nat Rev Cancer. 8(3): 193-204.
67. Hemminki, K. & Thilly, W.G. (1988). Binding of cisplatin to specific sequences of human DNA in vitro. Mutat Res. 202(1): 133-138.
68. Herman, J. G. & Baylin, S. B. (2003). Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 349(21): 2042-2054.
69. Hicks, J.K., Chute, C.L., Paulsen, M.T., Ragland, R.L., Howlett, N.G., Gueranger, Q., et al. (2010). Differential roles for DNA polymerases eta, zeta, and REV1 in lesion bypass of intrastrand versus interstrand DNA cross-links. Mol Cell Biol. 30(5): 1217-1230.
70. Hofr, C. & Brabec, V. (2001). Thermal and thermodynamic properties of duplex DNA containing site-specific interstrand cross-link of antitumor cisplatin or its clinically ineffective trans isomer. J Biol Chem. 276(13): 9655-9661.
71. Hofr, C., Farrell, N. & Brabec, V. (2001). Thermodynamic properties of duplex DNA containing a site-specific d(GpG) intrastrand crosslink formed by an antitumor dinuclear platinum complex. Nucleic Acids Res. 29(10): 2034-2040.
72. Hoffmann, J.S., Pillaire, M.J., Garcia-Estefania, D., Lapalu, S. & Villani, G. (1996). In vitro bypass replication of the cisplatin-d(GpG) lesion by calf thymus DNA polymerase beta and human immunodeficiency virus type I reverse transcriptase is highly mutagenic. J Biol Chem. 271(26): 15386-15392.
73. Hoffmann, J.S., Pillaire, M.J., Maga, G., Podust, V., Hubscher, U. & Villani G. (1995). DNA polymerase beta bypasses in vitro a single d(GpG)-cisplatin adduct placed on codon 13 of the HRAS gene. Proc Natl Acad Sci. USA. 92(12): 5356-5360.
74. Holler, E. (1993). Mechanism of action of tumor-inhibiting metal complexes. In: Metal complexes in cancer chemotherapy, Keppler, B.K. (edn.) VCH, Weinhein, pp. 37-71.
75. Holzer, A.K. & Howell, S.B. (2006). The internalization and degradation of human copper transporter 1 following cisplatin exposure. Cancer Res. 66(22): 10944-10952.
76. Holzer, A.K., Katano, K., Klomp, L.W. & Howell, S.B. (2004a). Cisplatin rapidly downregulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells. Clin Cancer Res. 10(19): 6744-6749.
77. Holzer, A.K., Manorek, G.H. & Howell, S.B. (2006a). Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin. Mol Pharmacol. 70(4): 1390-1394.
78. Holzer, A.K., Samimi, G., Katano, K., Naerdemann, W., Lin, X., Safaei, R, et al. (2004b). The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells. Mol Pharmacol. 66(4): 817-823.
79. Howell, S.B., Safaei, R., Larson, C.A. & Sailor, M.J. (2010). Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs. Mol Pharmacol. 77(6): 887-894.
80. Holzer, A.K., Varki, N.M., Le, Q.T., Gibson, M.A., Naredi, P. & Howell, S.B. (2006b). Expression of the human copper influx transporter 1 in normal and malignant human tissues. J Histochem Cytochem. 54(9): 1041-1049.
81. Holliday, R. (1987). The inheritance of epigenetic defects. Science. 238(4824): 163-170.
82. Hostetter, A.A., Chapman, E.G. & DeRose, V.J. (2009). Rapid cross-linking of an RNA internal loop by the anticancer drug cisplatin. J Am Chem Soc. 131(26): 9250-9257.
83. Hromas, R.A., North, J.A. & Burns, C.P. (1987). Decreased cisplatin uptake by resistant L1210 leukemia cells. Cancer Lett. 36(2): 197-201.
84. Ishida, S., Lee, J., Thiele, D.J. & Herskowitz, I. (2002). Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad. Sci. USA.. 99(22): 14298-14302.
85. Ishidaa, R., Takaokaa, Y., Yamamotoa, S., Miyazakia, T., Otakab, M., Watanabeb, S., et al. (2008). Cisplatin differently affects amino terminal and carboxyl terminal domains of HSP90. FEBS Lett. 582(28): 3879-3883.
86. Ishikawa, T. & Ali-Osman, F. (1993). Glutathione-associated cisdiamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance. J Biol Chem. 268(27): 20116-20125.
87. Ivanov, A.I., Christodoulou, J., Parkinson, J.A., Barnham, K.J., Tucker, A., Woodrow, J., et al. (1998). Cisplatin binding sites on human albumin. J Biol Chem. 273(24): 14721-14730.
88. Jakupec, M.A., Galanski, M. & Keppler, B.K. (2003). Tumour-inhibiting platinum complexes--state of the art and future perspectives. Rev Physiol Biochem Pharmacol. 146(1): 1-54.
89. Jandial, D.D., Farshchi-Heydari, S., Larson, C.A., Elliott, G.I., Wrasidlo, W.J. & Howell, S.B. (2009). Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1. Clin Cancer Res. 15(2): 553-560.
90. Johnson, R.D., Liu, N. & Jasin, M. 1999. Mammalian XRCC2 promotes the repair of DNA double-strand breaks by homologous recombination. Nature. 401(6751): 397-399.
91. Jordan, P. & Carmo-Fonseca, M. (1998). Cisplatin inhibits synthesis of ribosomal RNA in vivo. Nucleic Acids Res. 26(12): 2831-2836.
92. Jung, Y. & Lippard, S.J. (2003). Multiple states of stalled T7 RNA polymerase at DNA lesions generated by platinum anticancer agents. J Biol Chem. 278(52): 52084-52092.
93. Jung, Y. & Lippard, S.J. (2006). RNA polymerase II blockage by cisplatin-damaged DNA. Stability and polyubiquitylation of stalled polymerase. J Biol Chem. 281(3): 1361-1370.
94. Kartalou, M. & Essigmann, J.M. (2001). Recognition of cisplatin adducts by cellular proteins. Mutat Res. 478(1-2): 1-21.
95. Kashani-Sabet, M., Lu, Y., Leong, L., Haedicke, K. & Scanlon, K.J. (1990). Differential oncogene amplification in tumor cells from a patient treated with cisplatin and 5-fluorouracil. Eur J Cancer. 26(3): 383-390.
96. Kawai, K., Kamatani, N., Georges, E. & Ling, V. (1990). Identification of a membrane glycoprotein overexpressed in murine lymphoma sublines resistant to cisdiamminedichloroplatinum(II). J Biol Chem. 265(22): 13137-13142.
97. Kelley, S.L., Basu, A., Teicher, B.A., Hacker, M.P., Hamer, D.H. & Lazo, J.S. (1988). Overexpression of metallothionein confers resistance to anticancer drugs. Science. 241(4874): 1813-1815.
98. Kelley, M.R. & Fishel, M.L. (2008). DNA repair proteins as molecular targets for cancer therapeutics. Anticancer Agents Med Chem. 8(4): 417-425.
99. Kelman, A.D. & Buchbinder, M. (1978). Platinum-DNA crosslinking: platinum antitumor drug interactions with native lambda bacteriophage DNA studied using a restriction endonuclease. Biochemie. 60: 893-899.
100. Kennedy, R.D., Quinn, J.E., Mullan, P.B., Johnston, P.G. & Harkin, D.P. (2004). The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst. 96(22): 1659-1668.
101. Kharbanda, S., Ren, R., Pandey, P., Shafman, T.D., Feller, S.M., Weichselbaum, R.R. et al. (1995). Activation of the c-Abl tyrosine kinase in the stress response to DNA-damaging agents. Nature. 376(6543): 785-788.
102. Köberle, B., Payne, J., Grimaldi, K.A., Hartley, J.A. & Masters, J.R. (1996). DNA repair in cisplatin-sensitive and resistant human cell lines measured in specific genes by quantitative polymerase chain reaction. Biochem Pharmacol. 52(11): 1729-1734.
103. Konstantakou, E.G., Voutsinas, G.E., Karkoulis, P.K., Aravantinos, G., Margaritis, L.H. & Stravopodis, D.J. (2009). Human bladder cancer cells undergo cisplatin-induced apoptosis that is associated with p53-dependent and p53-independent responses. Int J Oncol. 35(2): 401-416.
104. Koshy, N., Quispe, D., Shi, R., Mansour, R. & Burton, G.V. (2010). Cisplatin-gemcitabine therapy in metastatic breast cancer: Improved outcome in triple negative breast cancer patients compared to non-triple negative patients. Breast. 19(3): 246-248.
105. Kraker, A.J. & Moore, C.W. (1988). Accumulaton of cis-diamminedichloroplatinum(II) and platinum analogues by platinum resistant murine leukemia cells in vitro. Cancer Res. 48(1): 9-13.
106. Kroemer, G., Zamzami, N. & Susin, S.A. (1997). Mitochondrial control of apoptosis. Immunol Today. 18(1): 44-51.
107. Kuo, Y.M., Zhou, B., Cosco, D. & Gitschier, J. (2001). The copper transporter CTR1 provides an essential function in mammalian embryonic development. Proc Natl Acad Sci. USA., 98(12): 6836-6841.
108. Lafarge, S., Sylvain, V., Ferrara, M. & Bignon, Y.J. (2001). Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. Oncogene. 20(45): 6597-6606.
109. Larson, C.A., Blair, B.G., Safaei, R. & Howell, S.B. (2009). The role of the mammalian copper transporter 1 in the cellular accumulation of platinum-based drugs. Mol Pharmacol. 75(2): 324-330.
110. Lemaire, M.A., Schwartz, A., Rahmouni, A.R. & Leng, M. (1991). Interstrand cross-links are preferentially formed at the d(GC) sites in the reaction between cisdiamminedichloroplatinum(II) and DNA. Proc Natl Acad. Sci. USA. 88(5): 1982-1985.
111. Li, L., Wang, H., Yang, E.S., Arteaga, C.L. & Xia, F. (2008). Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells. Cancer Res. 68(22): 9141-9146.
112. Lin, X., Okuda, T., Holzer, A. & Howell, S.B. (2002). The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae. Mol Pharmacol. 62(5): 1154-1159.
113. Loehrer, P.J. & Einhorn, L.H. (1984). Drug five years later. Cisplatin, Annals of Internal Medicine, 100, pp. 704-713.
114. Lujambio, A., Ropero, S., Ballestar, E., Fraga, M.F., Cerrato, C., Setien, F., et al. (2007). Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res. 67(4): 1424-1429.
115. Lyakhovich, A. & Shekhar, M. P. V. (2004). Supramolecular complex formation between Rad6 and proteins of the p53 pathway during DNA damage-induced response. Mol Cell Biol. 23(7): 2463-2475.
116. Mamenta, E.L., Poma, E.E., Kaufmann, W.K., Delmastro, D.A., Grady, H.L. & Chaney, S.G. (1994). Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res. 54(13): 3500-3505.
117. Mann, S.C., Andrews, P.A. & Howell, S.B. (1988). Comparison of lipid content, surface membrane fluidity, and temperature dependence of cis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Anticancer Res. 8(6): 1211-1215.
118. Mann, S.C., Andrews, P.A. & Howell, S.B. (1990). Short-term cis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Chemother Pharmacol. 25(4): 236-240.
119. Mann, S.C., Andrews, P.A. & Howell, S.B. (1991). Modulation of cis-diamminedichloroplatinum(II) accumulation and sensitivity by forskolin and 3-isobutyl-I-methylxanthine in sensitive and resistant human ovarian carcinoma cells. Int J Cancer. 48(6): 866-872.
120. Mansouri, A., Ridgway, L.D., Korapati, A.L., Zhang, Q., Tian, L., Wang, Y., et al. (2003). Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J Biol Chem. 278(21): 19245-19256.
121. Mullan, P.B., Gorski, J.J. & Harkin, D.P. (2006). BRCA1 - a good predictive marker of drug sensitivity in breast cancer treatment? Biochim Biophys Acta. 1766(2): 205-216.
122. Musah, R.A. (2004). The HIV-1 nucleocapsid zinc finger protein as a target of antiretroviral therapy. Curr Top Med Chem. 4(15): 1605-1622.
123. Neault, J.F., Benkirane, A., Malonga, H. & Tajmir-Riahi, H.A. (2001). Interaction of cisplatin drug with Na,K-ATPase: drug binding mode and protein secondary structure. J Inorg Biochem. 86(2-3): 603-609.
124. Neault, J.F. & Tajmir-Riahi, H.A. (1998). Interaction of cisplatin with human serum albumin. Drug binding mode and protein secondary structure. Biochim Biophys Acta. 1384(1): 153-159.
125. Nehme, A., Baskaran, R., Aebi, S., Fink, D., Nebel, S., Cenni, B. et al. (1997). Differential induction of c-Jun NH2-terminal kinase and c-Abl kinase in DNA mismatch repairproficient and -deficient cells exposed to cisplatin. Cancer Res. 57(15): 3253-3257.
126. Noda, S., Yoshimura, S., Sawada, M., Naganawa, T., Iwama, T., Nakashima, S., et al. (2001). Role of ceramide during cisplatin-induced apoptosis in C6 glioma cells. J Neurooncol. 52(1): 11-21.
127. Ober, M. & Lippard, S.J. (2008). A 1,2-d(GpG) cisplatin intrastrand cross-link influences the rotational and translational setting of DNA in nucleosomes. J Am Chem Soc. 130(9): 2851-2861.
128. O'Byrne, K.J., Barr, M.P. & Gray, S.G. (2011). The role of epigenetics in resistance to cisplatin chemotherapy in lung cancer. Cancer. 3: 1426-1453.
129. Oldenburg, J., Begg, A.C., van Vugt, M.J.H., Ruevekamp, M., Schornagel, J.H., Pinedo, H.M. & G. Los, G. (1994). Characterization of resistance mechanisms to cisdiamminedichloroplatinum(II) in three sublines of the CC531 colon adenocarcinoma cell line in vitro. Cancer Res. 54(2): 487-493.
130. Pabla, N., Murphy, R.F., Liu, K. & Dong, Z. (2009). The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am J Physiol Renal Physiol. 296(3): F505-F511.
131. Parker, R.J., Eastman, A., Bostick-Bruton, F. & Reed, E. (1991). Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J Clin Invest. 87(3): 772-777.
132. Parker, R.J., Poirier, M.C., Bostick-Bruton, F., Vionnet, J., Bohr, V.A. & Reed, E. (1990). The use of peripheral blood leukocytes as a surrogate marker for cisplatin drug resistance studies of adduct levels and ERCC1. Basic Life Sci. 53: 251-261.
133. Peklak-Scott, C., Smitherman, P.K., Townsend, A.J. & Morrow, C.S. (2008). Role of glutathione S-transferase P1-1 in the cellular detoxification of cisplatin. Mol Cancer Ther. 7(10): 3247-3255.
134. Pillaire, M.J., Margot, A., Villani, G., Sarasin, A., Defais, M. & Gentil, A. (1994). Mutagenesis in monkey cells of a vector containing a single d(GpG cisdiamminedichloroplatinum(II) adduct placed on codon 13 of the human H-ras protooncogene. Nucleic Acids Res. 22(13): 2519-2524.
135. Pinto, A.L. & Lippard, S.J. (1985). Binding of the antitumor drug cisdiamminedichloroplatinum(II)(cisplatin) to DNA. Biochim Biophys Acta.. 780(3): 167-180.
136. Pogribny, I.P., Filkowski, J.N., Tryndyak, V.P., Golubov, A., Shpyleva, S.I. & Kovalchuk, O. (2010). Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Int J Cancer. 127: 1785-1794.
137. Powell, S.N. & Bindra, R.S. (2009). Targeting the DNA damage response for cancer therapy. DNA Repair. 8(9): 1153-1165.
138. Pratt, W.R., Ruddon, R.W., Ensminger, W.D & Maybaum, J. (1994). The anticancer drugs 2nd, Oxford University press, New York, USA.
139. Price, M. & Monteiro, A.N.A. (2010). Fine tuning chemotherapy to match BRCA1 status. Biochem Pharmacol. 80(5): 647-653.
140. Qiu, Y.Y., Mirkin, B.L. & Dwivedi, R.S. (2005). Inhibition of DNA methyltransferase reverses cisplatin induced drug resistance in murine neuroblastoma cells. Cancer Detect Prev. 29: 456-463.
141. Quinn, J.E., Carser, J.E., James, C.R., Kennedy, R.D. & Harkin, D.P. (2009). BRCA1 and implications for response to chemotherapy in ovarian cancer. Gynecol Oncol. 113(1): 134-142.
142. Quinn, J.E., James, C,R., Stewart, G.E., Mulligan, J.M., White, P., Chang, G.K., et al. (2007). BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res. 13(24): 7413-7420.
143. Quinn, J.E., Kennedy, R.E., Mullan, P.B., Gilmore, P.M., Carty, M., Johnston, P.G., et al. (2003). BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res. 63(19): 6221-6228.
144. Ratanaphan, A., Canyuk, B., Wasiksiri, S. & Mahasawat, P. (2005). In vitro platination of human breast cancer suppressor gene1 (BRCA1) by the anticancer drug carboplatin, Biochim Biophys Acta. 1725(2): 145-151.
145. Ratanaphan, A., Wasiksiri, S., Canyuk, B. & Prasertsan P. (2009). Cisplatin-damaged BRCA1 exhibits altered thermostability and transcriptional transctivation. Cancer Biol Ther. 8(10): 890-898.
146. Reed, E. Ozols, R.F., Tarone, R., Yuspa, S.H. & Poirier, M.C. (1987). Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. Proc Natl Acad Sci. USA. 84(14): 5024-5028.
147. Reed, J.C. (2002). Apoptosis-based therapies. Nat Rev-Drug Discov. 1(2): 111-121.
148. Reeves, R. (1984). Transcriptionally active chromatin. Biochim Biophys Acta. 782(4): 343-393.
149. Rosenberg, B., VanCamp, L. & Krisgas, T. (1965). Inhibition of cell devision in Escherichia coli by electrolysis products from a platinum electrod. Nature. 205(4972): 698- 699.
150. Rosenberg, B., Renshaw, E., VanCamp, L., Hartwick, J. & Drobnik. J. (1967). Platinum induced filamentous growth in Escherichia coli. J Bacteriol. 93(2): 716-721.
151. Rosenberg, B., VanCamp, L., Trosko, J.E. & Mansour, V.H. (1969). Platinum compounds: a new class of potent antitumor agents. Nature. 222(191): 385-386.
152. Rosenberg, J. M. & Sato, P. H. (1988). Messenger RNA loses the ability to direct in vitro peptide synthesis following incubation with cisplatin. Mol Pharmacol. 33(6): 611-616.
153. Rosenberg, J.M. & Sato, P.H. (1993). Cisplatin inhibits in vitro translation by preventing the formation of complete initiation complex. Mol Pharmacol. 43(3): 491-497.
154. Royer - Pokora, B., Gordon, I. K. & Haseltine, W. A. (1981). Use of exonuclease III to determine the site of stable lesions in defined sequences of DNA: the cytobutane pyrimidine dimmer and cis- and trans- dichlorodiammineplatinum(II) examples. Nucleic Acids Res. 9(18): 4595-4609.
155. Safaei, R. (2006). Role of copper transporters in the uptake and efflux of platinum containing drugs. Cancer Lett. 234(1): 34-39.
156. Safaei, R., Katano, K., Samimi, G., Naerdemann, W., Stevenson, J. L., Rochdi, M., et al. (2004). Cross-resistance to cisplatin in cells with acquired resistance to copper. Cancer Chemother Pharmacol. 53(3): 239-246.
157. Safaei, R., Otani, S., Larson, B. J., Rasmussen, M. L. & Howell, S.B. (2008). Transport of cisplatin by the copper efflux transporter ATP7B. Mol Pharmacol. 73(2): 461-468.
158. Saga, Y., Hashimoto, H., Yachiku, S., Iwata, T. & Tokumitsu, M. (2004). Reversal of acquired cisplatin resistance by modulation of metallothionein in transplanted murine tumors. Int J Urol. 11(6): 407-415.
159. Saito, Y., Liang, G., Egger, G., Friedman, J.M., Chuang, J.C., Coetzee, G.A., et al. (2006). Specific activation of micro RNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell. 9(6): 435-443.
160. Sato, K., Hayami, R., Wu, W., Nishikawa, T., Nishikawa, H., Okuda, Y., et al. (2004). Nucleophosmin/B23 is a candidate substrate for the BRCA1-BARD1 ubiquitin ligase. J Biol Chem. 279(30): 30919-30922.
161. Sato, P.H., Rosenberg, J.M. & Sato, R.I. (1996). Differences in the inhibition of translation by cisplatin, transplatin, and certain related compounds. Biochem Pharmacol. 52(12): 1895-1902.
162. Scanlon, K.J., Kashani-Sabet, M., Miyachi, H., Sowers, L.C. & Rossi, J.J. (1989). Molecular basis of cisplatin resistance in human carcinomas: model systems and patients. Anticancer Res. 9(5): 1310-1312.
163. Selvakumaran, M., Pisarcik, D.A., Bao, R., Yeung, A.T. & Hamilton, T.C. (2003). Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res. 63(6): 1311-1316.
164. Sherman, S.E. & Lippard, S.J. (1987). Structural aspects of platinum anticancer drug interactions with DNA. Chem Rev. 87(5): 1153-1181.
165. Silver, D.P., Richardson, A.L., Eklund, A.C., Wang, Z.C., Szallasi, Z., Li, O., et al. (2010). Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol. 28(7): 1145-1153.
166. Sirohi, B., Arnedos, M., Popat, S., Ashley, S., Nerurkar, A., Walsh, G., et al. (2008). Platinum-based chemotherapy in triple-negative breast cancer. Ann. Oncol. 19(11): 1847-1852.
167. Sklar, M. (1988). Increased resistance to cis-diamminedichloroplatinum(II) in NIH 3T3 cells transformed by ras oncogenes. Cancer Res. 48(4): 793-797.
168. Suddek, G.M. (2011). Sunitinib improves chemotherapeutic efficacy and ameliorates cisplatin-induced nephrotoxicity in experimental animals. Cancer Chemother Pharmacol. 67(5): 1035-1044.
169. Sun, X., Tsang, C-N. & Sun, H. (2009). Identification and characterization of metallodrug binding proteins by (metallo)proteomics. Metallomics. 1(1): 25-31.
170. Swisher, E.M., Sakai, W., Karlan, B.Y., Wurz, K., Urban, N. & Taniguchi, T. (2008). Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res. 68(8): 2581-2586.
171. Taron, M., Rosell, R., Felip, E., Mendez, P., Souglakos, J., Ronco, M.S., et al. (2004). BRCA1 mRNA expression as an indicator of chemoresistance in lung cancer. Hum Mol Genet. 13(20): 2443-2449.
172. Tassone, P., Martino, M.T.D., Ventura, M., Pietragalla, A., Cucinotto, I., Calimeri, T., et al. (2009). Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo. Cancer Biol Ther. 8(7): 648-653.
173. Tassone, P., Tagliaferri, P., Perricelli, A., Blotta, S., Quaresima, B., Martelli, M.L., et al. (2003). BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer. 88(8): 1285-1291.
174. Teicher, B.A., Holden, S.A., Kelley, M.J., Shea, T.C., Cucchi, C.A., Rosowsky, A., et al. (1987). III. Characterization of a human squamous carcinoma cell line resistant to cisdiamminedichloroplatinum(II). Cancer Res. 47(2): 388-393.
175. Timerbaev, A.R., Hartinger, C.G., Aleksenko, S.S. & Keppler, B.K. (2006). Interactions of antitumor metallodrugs with serum proteins: advances in characterization using modern analytical methodology. Chem Rev. 106(6): 2224-2248.
176. Tornaletti, S., Patrick, S.M., Turchi, J.J. & Hanawalt, P.C. (2003). Behavior of T7 RNA polymerase and mammalian RNA polymerase II at site-specific cisplatin adducts in the template DNA. J Biol Chem. 278(37): 35791-35797.
177. Treiber, D.K., Zhai, X., Jantzen, H.M. & Essigmann, J.M. (1994). Cisplatin-DNA adducts are molecular decoys for the ribosomal RNA transcription factor hUBF (human upstream binding factor). Proc Natl Acad. Sci. USA. 91(12): 5672-5676.
178. Tullius, T.D. & Lippard, S.J. (1981). Cis-Diamminedichloroplatinum(II) binds in a unique manner to oligo(dG)oligo(dC) sequences in DNA-A new assay using exonuclease III. J Am Chem Soc. 103(15): 4620-4622.
179. Vichi, P., Coin, F., Renaud, J-P., Vermeulen, W., Hoeijmakers, J.H.J., Moras, D. et al. (1997). Cisplatin- and UV-damaged DNA lure the basal transcription factor TFIID/TBP. EMBO J. 16(24): 7444-7456.
180. Wang, D. & Lippard, S.J. (2005). Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov. 4(4): 307-320.
181. Wang, W. & Figg, W.D. (2008). Secondary BRCA1 and BRCA2 alterations and acquired chemoresistance. Cancer Biol Ther. 7(7): 1004-1005.
182. Waud, W.R. (1987). Differential uptake of cis-diamminedichloroplatinum(II) by sensitive and resistant murine L1210 leukemia cells. Cancer Res. 47: 6549-6555.
183. Wilkins, R. J. & Hart, R. W. (1974). Preferential DNA repair in human cells. Nature. 247(5435): 35-36.
184. Wong, S.W., Tiong, K.H. & Kong, W.Y. (2011). Rapamycin synergizes cisplatin sensitivity in basal-like breast cancer cells through up-regulation of p73. Breast Cancer Res Treat. 128(2): 301-313.
185. Wu, B., Droege, P. & Davey, C.A. (2008). Site selectivity of platinum anticancer therapeutics. Nat Chem Biol. 4(2): 110-112.
186. Wu, Z., Liu, Q., Liang, X., Yang, X., Wang, N., Wang, X., et al. (2009). Reactivity of platinum-based antitumor drugs towards a Met- and His-rich 20 mer peptide corresponding to the N-terminal domain of human copper transporter 1. J Biol Inorg Chem. 14(8): 1313-1323.
187. Young, R.C., Fuks, Z. & Hoskins, W.J. (1989). Cancer of the ovary, In: Cancer principles and practice of oncology, (ed.) Devita, Jr., V.T., et al., Lippincott, J.B., Philadelphia, pp. 1162-1196.
188. Zamble, D.B. & Lippard, S.J. (1995). Cisplatin and DNA repair in cancer therapy. Trends Biochem Sci. 20(10): 435-439.
189. Zamble, D.B., Mu, D., Reardon, J.T., Sancar, A. & Lippard, S.J. (1996). Repair of cisplatin-DNA adducts by the mammalian excision nuclease. Biochemistry. 35: 1004-1013.
190. Zhao, T., King, F.L. (2009). Direct determination of the primary binding site of cisplatin on cytochrome c by mass spectrometry. J Am Soc Mass Spectrom. 20(6): 1141-1147.
191. Zhen, W., Link, Jr.C.J., O'Connor, P.M., Reed, E., Parker, R., Howell, S.B., et al. (1992). Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines. Mol Cell Biol. 12(9): 3689-3698.
192. Zhu, Y., Hub, J., Hu, Y. & Liu, W. (2009). Targeting DNA repair pathways: a novel approach to reduce cancer therapeutic resistance. Cancer Treat Rev. 35(7): 590-596.
193. Zwelling, L.A. & Kohn, K.W. (1982). Platinum complexes. In: Chabner BA, edn. Pharmacologic principle of cancer treatment. Philadelphia: WB Saunders: USA.